MCID: TRP003
MIFTS: 33

Triple-Receptor Negative Breast Cancer

Categories: Cancer diseases

Aliases & Classifications for Triple-Receptor Negative Breast Cancer

MalaCards integrated aliases for Triple-Receptor Negative Breast Cancer:

Name: Triple-Receptor Negative Breast Cancer 12 14

Classifications:



External Ids:

Disease Ontology 12 DOID:0060081

Summaries for Triple-Receptor Negative Breast Cancer

MalaCards based summary : Triple-Receptor Negative Breast Cancer is related to gastritis and nerve fibre bundle defect. An important gene associated with Triple-Receptor Negative Breast Cancer is ATF5 (Activating Transcription Factor 5), and among its related pathways/superpathways are PI3K-Akt signaling pathway and MicroRNAs in cancer. The drugs Pembrolizumab and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include breast and brain, and related phenotypes are cardiovascular system and cellular

Related Diseases for Triple-Receptor Negative Breast Cancer

Diseases related to Triple-Receptor Negative Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 92)
id Related Disease Score Top Affiliating Genes
1 gastritis 10.7 ERBB2 PGR
2 nerve fibre bundle defect 10.7 ERBB2 ESR1
3 bartholin's gland benign neoplasm 10.7 ESR1 PGR
4 central nervous system organ benign neoplasm 10.7 ESR1 PGR
5 gallbladder leiomyoma 10.7 ESR1 PGR
6 lung adenoma 10.7 ESR1 PGR
7 skin sarcoma 10.7 ERBB2 PGR
8 fallopian tube benign neoplasm 10.6 ESR1 PGR
9 paranasal sinus disease 10.6 ESR1 PGR
10 her2-receptor negative breast cancer 10.6 ERBB2 PGR
11 dartoic leiomyoma 10.6 ESR1 PGR
12 cutaneous lupus erythematosus 10.6 BRCA1 ERBB2
13 urinary bladder inverted papilloma 10.6 ESR1 PGR
14 lymphocytic infiltrate of jessner 10.6 PGR TSC2
15 deafness, autosomal dominant 8/12 10.6 ESR1 PGR
16 endocervicitis 10.6 BRCA1 ERBB2
17 intestinal perforation 10.6 ESR1 PGR
18 superficial basal cell carcinoma 10.5 ESR1 PGR
19 sarcomatoid squamous cell skin carcinoma 10.5 ESR1 PGR
20 autoimmune disease of blood 10.5 BRCA1 PGR
21 pineal region meningioma 10.5 ESR1 PGR
22 selective immunoglobulin deficiency disease 10.5 BRCA1 PGR
23 bladder colloid adenocarcinoma 10.5 ESR1 PGR
24 glaucoma, hereditary 10.5 ERBB2 ESR1 PGR
25 subglottis verrucous carcinoma 10.5 ERBB2 ESR1 PGR
26 ovarian mesodermal adenosarcoma 10.5 ESR1 PGR
27 gastric tubular adenocarcinoma 10.5 ERBB2 ESR1 PGR
28 her2-receptor positive breast cancer 10.5 ERBB2 ESR1 PGR
29 gastroesophageal junction adenocarcinoma 10.5 ERBB2 ESR1 PGR
30 kidney clear cell sarcoma 10.5 ERBB2 ESR1 PGR
31 endophthalmitis 10.5 ESR1 PGR
32 dmd-related dilated cardiomyopathy 10.5 ERBB2 ESR1 PGR
33 organ system benign neoplasm 10.5 ERBB2 ESR1 PGR
34 cartilage cancer 10.5 ERBB2 ESR1 PGR
35 malignant thyroid stimulating hormone producing neoplasm of pituitary gland 10.5 ERBB2 ESR1 PGR
36 hypersensitivity reaction type iii disease 10.5 ERBB2 ESR1 PGR
37 comedo carcinoma 10.5 ERBB2 ESR1 PGR
38 anal paget's disease 10.5 ERBB2 ESR1 PGR
39 osteogenesis imperfecta 10.5 ESR1 PGR
40 ureter adenocarcinoma 10.5 ERBB2 ESR1 PGR
41 lacrimal gland mucoepidermoid carcinoma 10.5 ERBB2 ESR1 PGR
42 vulva adenocarcinoma 10.4 ERBB2 ESR1 PGR
43 retinal disease 10.4 ERBB2 ESR1 PGR
44 progesterone-receptor negative breast cancer 10.4 ERBB2 ESR1 PGR
45 breast duct papilloma 10.4 ERBB2 ESR1 PGR
46 mixed cerebral palsy 10.4 ERBB2 ESR1 PGR
47 progesterone-receptor positive breast cancer 10.4 ERBB2 ESR1 PGR
48 kallmann syndrome 10.4 ERBB2 PGR
49 endometriosis of uterus 10.4 ERBB2 ESR1 PGR
50 brenner tumor of the vagina 10.4 BRCA1 ERBB2 ESR1

Graphical network of the top 20 diseases related to Triple-Receptor Negative Breast Cancer:



Diseases related to Triple-Receptor Negative Breast Cancer

Symptoms & Phenotypes for Triple-Receptor Negative Breast Cancer

MGI Mouse Phenotypes related to Triple-Receptor Negative Breast Cancer:

44 (show all 13)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.22 BRCA1 ERBB2 ESR1 IGFBP2 PGR RPS6KB1
2 cellular MP:0005384 10.21 BRCA1 DAPK1 ERBB2 ESR1 MCL1 PARP1
3 homeostasis/metabolism MP:0005376 10.2 STMN1 TFEC TSC2 BRCA1 DAPK1 ERBB2
4 embryo MP:0005380 10.19 BRCA1 ERBB2 ESR1 MCL1 PARP1 PGR
5 mortality/aging MP:0010768 10.14 ATF5 BRCA1 ERBB2 ESR1 MCL1 PARP1
6 integument MP:0010771 10.13 BRCA1 ERBB2 ESR1 MCL1 PARP1 PGR
7 endocrine/exocrine gland MP:0005379 10.08 BRCA1 ERBB2 ESR1 MCL1 PGR RPS6KB1
8 nervous system MP:0003631 9.96 STMN1 TSC2 USP9X ATF5 BRCA1 DAPK1
9 normal MP:0002873 9.93 BRCA1 ERBB2 ESR1 IGFBP2 MCL1 MSLN
10 neoplasm MP:0002006 9.92 BRCA1 ERBB2 ESR1 PGR RPS6KB1 STK11
11 muscle MP:0005369 9.91 BRCA1 ERBB2 ESR1 PGR RPS6KB1 STK11
12 renal/urinary system MP:0005367 9.5 BRCA1 DAPK1 ESR1 IGFBP2 PARP1 STK11
13 reproductive system MP:0005389 9.28 BRCA1 ERBB2 ESR1 MCL1 PARP1 PGR

Drugs & Therapeutics for Triple-Receptor Negative Breast Cancer

Drugs for Triple-Receptor Negative Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 32)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pembrolizumab Approved Phase 3 1374853-91-4
2
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
3
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
4
Gemcitabine Approved Phase 2 95058-81-4 60750
5
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
6
Vinorelbine Approved, Investigational Phase 2 71486-22-1 60780 44424639
7
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
8
Epirubicin Approved Phase 2 56420-45-2 41867
9
Everolimus Approved Phase 2 159351-69-6 6442177
10
Fluorouracil Approved Phase 2 51-21-8 3385
11
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
12
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
13
Docetaxel Approved May 1996, Investigational Phase 2 114977-28-5 148124 9877265
14 Albumin-Bound Paclitaxel Phase 2
15 Antimitotic Agents Phase 2
16 Antineoplastic Agents, Phytogenic Phase 2
17 Angiogenesis Inhibitors Phase 2
18 Angiogenesis Modulating Agents Phase 2
19 Alkylating Agents Phase 2
20 Anti-Bacterial Agents Phase 2
21 Antibiotics, Antitubercular Phase 2
22 Antifungal Agents Phase 2
23 Anti-Infective Agents Phase 2
24 Antimetabolites Phase 2
25 Antimetabolites, Antineoplastic Phase 2
26 Antirheumatic Agents Phase 2
27 Immunosuppressive Agents Phase 2
28 Topoisomerase Inhibitors Phase 2
29
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
30 Mitogens Phase 2
31 Protein Kinase Inhibitors Phase 2
32 taxane Phase 2

Interventional clinical trials:


id Name Status NCT ID Phase Drugs
1 Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer Recruiting NCT02954874 Phase 3
2 EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients Completed NCT00448305 Phase 2 EndoTAG-1 + paclitaxel;EndoTAG-1;Paclitaxel
3 Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer Completed NCT00246571 Phase 2 SU011248;Chemotherapy
4 Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer Active, not recruiting NCT00499603 Phase 2 Paclitaxel;5-Fluorouracil;Epirubicin;Cyclophosphamide;RAD001
5 Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer Terminated NCT00739063 Phase 2 Tarceva
6 A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations Terminated NCT02299635 Phase 2 PF-03084014;PF-03084014;PF-03084014

Search NIH Clinical Center for Triple-Receptor Negative Breast Cancer

Genetic Tests for Triple-Receptor Negative Breast Cancer

Anatomical Context for Triple-Receptor Negative Breast Cancer

MalaCards organs/tissues related to Triple-Receptor Negative Breast Cancer:

39
Breast, Brain

Publications for Triple-Receptor Negative Breast Cancer

Articles related to Triple-Receptor Negative Breast Cancer:

(show all 11)
id Title Authors Year
1
The unmet need for effective treatment of triple-receptor negative breast cancer. ( 25768894 )
2014
2
Mesothelin expression and survival outcomes in triple receptor negative breast cancer. ( 23810431 )
2013
3
Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. ( 21800293 )
2012
4
Triple receptor-negative breast cancer: imaging and clinical characteristics. ( 22826413 )
2012
5
Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer. ( 22359359 )
2012
6
Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. ( 21233401 )
2011
7
Capecitabine in operable triple receptor-negative breast cancer: A subgroup analysis of a randomized phase III trial. ( 27958045 )
2011
8
Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer? ( 20580045 )
2010
9
Survival among women with triple receptor-negative breast cancer and brain metastases. ( 19150943 )
2009
10
Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. ( 19047281 )
2009
11
Advances in triple receptor-negative breast cancer. ( 18277956 )
2007

Variations for Triple-Receptor Negative Breast Cancer

Expression for Triple-Receptor Negative Breast Cancer

Search GEO for disease gene expression data for Triple-Receptor Negative Breast Cancer.

Pathways for Triple-Receptor Negative Breast Cancer

GO Terms for Triple-Receptor Negative Breast Cancer

Cellular components related to Triple-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.28 ATF5 BRCA1 ESR1 MCL1 PARP1 PGR

Biological processes related to Triple-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.8 ATF5 BRCA1 ESR1 PARP1 PGR TFEC
2 regulation of apoptotic process GO:0042981 9.56 BRCA1 DAPK1 ESR1 MCL1
3 regulation of DNA methylation GO:0044030 9.37 BRCA1 PARP1
4 anoikis GO:0043276 9.16 STK11 TSC2
5 response to estrogen GO:0043627 9.13 BRCA1 ESR1 IGFBP2
6 apoptotic process GO:0006915 9.02 BRCA1 DAPK1 MCL1 RPS6KB1 STK11

Molecular functions related to Triple-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.53 ATF5 BRCA1 DAPK1 ERBB2 ESR1 IGFBP2
2 tubulin binding GO:0015631 9.13 ATF5 BRCA1 STMN1

Sources for Triple-Receptor Negative Breast Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....